ABBV vs AVGO: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Broadcom Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Broadcom Inc. · Technology
$371.59
-49.9% upside to fair value
Grade C
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(+4.5%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
AVGO |
| Current Price |
$208.05 |
$371.59 |
| Fair Value Estimate |
$217.50 |
$186.35 |
| Upside to Fair Value |
+4.5%
|
-49.9%
|
| Market Cap |
$367.9B |
$1,761.8B |
| Forward P/E |
14.9x
|
70.7x
|
| EV / EBITDA |
16.7x
|
46.7x
|
| Price / Sales |
6.1x
|
25.9x
|
| Price / FCF |
20.9x
|
61.1x
|
| Revenue Growth YoY |
+8.6%
|
+7.2%
|
| Gross Margin |
83.7%
|
67.1%
|
| Operating Margin |
34.7%
|
40.9%
|
| Return on Equity |
-129.24%
|
32.9%
|
| Dividend Yield |
3.2% |
0% |
| FCF Yield |
4.78%
|
1.64%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Broadcom Inc. is a leading technology company specializing in semiconductors and infrastructure software, with a strong competitive moat driven by scale, diversification, and aggressive M&A under CEO Hock E. Tan. The company has demonstrated robust revenue growth, particularly in semiconductor solutions and infrastructure software segments, with a 25% year-over-year increase recently and a five-y…
Accumulation Zones
| Metric |
ABBV |
AVGO |
| Zone Low |
$163.13 |
$139.76 |
| Zone High |
$184.88 |
$158.40 |
| In Buy Zone? |
No
|
No
|